Thomas J. Schall
2021
In 2021, Thomas J. Schall earned a total compensation of $9M as President and Chief Executive Officer at ChemoCentryx, a 7% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $464,563 |
|---|---|
| Option Awards | $2,568,826 |
| Salary | $737,401 |
| Stock Awards | $5,203,730 |
| Other | $3,564 |
| Total | $8,978,084 |
Schall received $5.2M in stock awards, accounting for 58% of the total pay in 2021.
Schall also received $464.6K in non-equity incentive plan, $2.6M in option awards, $737.4K in salary and $3.6K in other compensation.
Rankings
In 2021, Thomas J. Schall's compensation ranked 1,232nd out of 12,415 executives tracked by ExecPay. In other words, Schall earned more than 90.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,232 out of 12,415 | 90th |
Division Manufacturing | 442 out of 5,508 | 92nd |
Major group Chemicals And Allied Products | 159 out of 2,378 | 93rd |
Industry group Drugs | 132 out of 2,099 | 94th |
Industry Pharmaceutical Preparations | 87 out of 1,549 | 94th |
Source: SEC filing on April 5, 2022.
Schall's colleagues
We found four more compensation records of executives who worked with Thomas J. Schall at ChemoCentryx in 2021.